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Summary Prognostic factors are needed for the management of patients with adrenocortical tumours. For
this reason, the nuclear DNA content of patients with adrenocortical tumours was analysed by flow
cytometry. The relationships between nuclear DNA content, histological indices, and clinical parameters were
studied. DNA ploidy could be evaluated in 54 carcinoma and 31 adenoma patients. Twenty-one (68%) of the
adenomas, and 6 (11%) of the carcinomas, were DNA diploid. Hypo/Hyperdiploidy was found in 5 (16%) of
the adenomas, and 15 (28%) of the carcinomas. The remaining patients had a DNA index above 1.40. A
shorter survival was found in patients with diploid carcinomas (P<0.05). A longer disease-free survival was
seen in patients with hypo/hyperdiploid carcinomas (P<0.05). Nuclear DNA content was not related to the
histological index, nor to clinical parameters. We conclude that nuclear DNA content is related to (disease-
free) survival of patients with adrenocortical carcinomas. An adenoma-carcinoma sequence may be present in
the adrenal cortex. In adrenocortical tumours ploidy evolution appears to be different than that observed in
other solid tumours.
Adrenocortical carcinoma is a rare disease with a poor prog-
nosis. The best chance of survival for a patient with
adrenocortical carcinoma is when a complete tumour resec-
tion can be performed.
Prognostic factors are needed to identify patients who
should be treated with mitotane, the drug of choice for
patients with inoperable, recurrent, and metastatic disease
(Samaan & Hickey, 1987), and those for which a less aggres-
sive approach is warranted. In addition, prognostic factors
could be used in deciding to treat patients in an adjuvant
setting with mitotane, not in the least because the
differentiation between benign and malignant tumours may
be difficult.
The histological index, determined by seven morphological
characteristics (van Slooten et al., 1985) was found to be
useful in the differentiation between malignant and benign
adrenocortical tumours. However, despite the determination
of this index, the assessment of the grade of malignancy is
not always certain.
Flow cytometric nuclear DNA content analysis has been
shown to be able to predict prognosis in several types of
human cancer (Cornelisse & Tanke, 1991). In adrenocortical
tumours DNA ploidy analysis has been performed however,
in too few cases to confidently judge the prognostic implica-
tions of this technique in these patients.
To evaluate the prognostic value of nuclear DNA content
on survival of patients with adrenocortical carcinoma, and to
establish the relationship between nuclear DNA content and
the histological index, we studied paraffin embedded or fresh
tumour tissue in 149 patients with adrenocortical tumours.
Materials and methods
One hundred and forty-nine patients with adrenocortical
tumours (96 carcinomas and 53 adenomas) were evaluated
and followed up in the Department of Endocrinology of the
University Hospital of Leiden from 1959 to 1992. The diag-
nosis adenoma and carcinoma was reconfirmed, in all cases.
When metastases were present the diagnosis carcinoma was
certain. Without the presence of metastases, the diagnosis
carcinoma was considered certain when the tumour had a
high weight (>150 g), and/or a mixed hormonal syndrome
with loss of precursor steroids in the urine as described by
van Slooten et al. (1984b). The diagnosis adenoma was con-
sidered certain when clinical presentation did not suggest a
carcinoma, when the tumour weight was below 30 g, or when
tumour weight was between 30 and 150 g and no loss of
precursor steroids was found in the 24 h collected urine.
Surgical excision of the tumour was always performed
when the patient's clinical condition permitted it. Surgical
resection of the tumour was considered total, when local
disease could be completely resected. Tumour resection was
considered subtotal in the case of post-operative macro-
scopically, or microscopically residual tumour tissue, or in
the case of metastatic disease.
Mitotane therapy was given to patients with metastatic
disease, after subtotal tumour resection, or as adjuvant after
total tumour resection. Maintenance mitotane serum levels,
determined according to the method previously described
(Moolenaar et al., 1977) were classified as low (<14mg 1')
or high (> 14 mgI`) (van Slooten et al., 1984a). Other
chemotherapeutic agents were given in addition to mitotane
in the presence of tumour progression, when the patient
refused mitotane therapy, or as judged by the attending
physician.
Flow cytometry
The procedures used for cell preparation and the staining of
fresh and paraffin embedded tissue have been described
elsewhere (Cornelisse et al., 1987). Briefly, five sections were
cut: 3 of 50 ttm for DNA analysis and adjacent to these
(before and after), two sections of 5 glm for light microscopy
to determine whether there was an adequate amount of,
representative, tumour tissue in the sections. Suspensions of
isolated nuclei were prepared from fresh or frozen tissue
specimens according to the detergent-trypsin procedure and
stained with propidium iodide (PI) containing 0.25 gLgml-'
RNAse (Vindelov et al., 1983). Rainbow trout red blood cells
were added to the suspensions of isolated nuclei prepared
from fresh or frozen samples as an internal ploidy standard.
The pepsin-digestion technique was used to release nuclei
from sections of paraffin-embedded tumour specimens ac-
cording to Hedley et al. (1983) with a slight modification
(Rodenburg et al., 1987).
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Deparaffinised samples were stained with 4' .6,-diamidino-
2-phenylindol (DAPI) (ICP-22 flow cytometer) or PI (FACS-
can flow cytometer). Measurements were initially made with
an ICP-22 flow cytometer and later, when the ICP-22 flow
cytometer was replaced in the laboratory, with a FACScan
flow cytometer (Becton and Dickinson, Mountain View, CA,
USA) with the use of the appropriate filter combinations for
the excitation of DAPI and PI fluorescence, respectively.
DNA profiles produced by the two instruments had a similar
resolution, and did not show systematic differences. Fresh
tumour tissue was analysed when available. Paraffin-
embedded tissue was taken of the archival material.
The histograms were assessed by two authors (HRH,
CJC). The interpretation of histograms has been described
before (Cornelisse et al., 1987). DNA profiles showing only a
single GO/GI peak were classified as DNA diploid, if the
coefficient of variation (CV) was <5.5%, or 'wide CV' dip-
loid, if CV exceeded 5.5%. Tumours with an additional
GO/GI peak were classified as aneuploid. Tumour ploidy was
expressed as the DNA index (DI), i.e., the ratio between the
modal channel number of the aneuploid GO/GI peak and that
of the diploid GO/GI peak. A further classification was made,
as in a previous study (Beerman et al., 1990) according to the
DNA index: DI 1.00 = diploid ('wide CV' diploid included);
DI 1.01-1.40, or DI s,0.99 = hypo/hyperdiploid; DI 1.41-
1.89, or DI ) 2.11 = hypo/hypertetraploid; DI 1.90-2.10 =
tetraploid. All tumours with more than one (aneuploid) stem-
line were subdivided according to the stemline with the
highest DNA index.
No attempt was made to calculate S-phase fractions,
because of differences in the resolution and quality of the
DNA profiles obtained from fresh versus deparaffinised sam-
ples, and because in addition two different flow cytometers
had to be used. The number of patients, were S-phase frac-
tion could be calculated and could be compared for different
clinico-pathological variables, is too low to draw con-
clusions.
Histological Index
The histological index of the tumours, from which nuclear
DNA content could be obtained, was assessed according to
the criteria of van Slooten et al. (1985). The histological
index was calculated using seven parameters, i.e., regressive
changes, preservation of normal structure, nuclear atypia,
nuclear hyperchromasia, structure of nucleoli, mitotic
activity, and invasion of the capsule and/or vascular walls.
Each of these parameters, when abnormal, has a specific
discriminating value (5.7, 1.6, 2.1, 2.6, 4.1, 9.0, and 3.3,
respectively).
Statistical analysis
DNA classes were compared with chi-square tests (qualitative
parameters), and analysis of variance (quantitative
parameters). The histological index, and individual mor-
phological parameters, were compared with t-tests. Survival
curves, calculated from time of diagnosis to the time of
death, and disease free-survival curves, calculated from the
time of diagnosis to the time of tumour recurrence, were
analysed by the Kaplan-Meier method. The Lee-Desu statis-
tic test was used for comparison of survival curves (Mathews
& Farewell, 1985).
Results
Relevant tissue blocks of40 historical patients (33 carcinoma
and seven adenoma) had been lost for follow up and thus
were not available for the study. Of the remaining 109
patients the histograms of 24 (nine carcinoma and 15
adenoma) could not be evaluated. The poor quality of the
histograms of these 24 tumours is explained by the use of
Bouin's fluid as fixative (Hedley, 1989). The remaining 85
patients (54 carcinomas, 31 adenomas) could be studied. The
diagnosis adrenocortical carcinoma or adenoma was con-
sidered certain in each case. The clinical characteristics of
these patients are shown in Table I.
DNAflow cytometry
Paraffin-embedded tissue was evaluated in 29 carcinomas and
17 adenomas with the ICP-22 flow cytometer and in 16
carcinomas and nine adenomas with the FACScan flow
cytometer. Fresh tissue was studied in four carcinomas and
one adenoma with the ICP-22 flow cytometer and in five
carcinomas and four adenomas with the FACScan flow
cytometer.
The CV of the 46 paraffin-embedded tumours studied on
the ICP-22 flow cytometer ranged between 2.8 and 9.0, with
a mean of 5.75 and a median of 5.9. DNA index of the 25
paraffin-embedded tumours studied on the FACScan flow
cytometer ranged between 3.7 and 9.9, with a mean of 6.3
and a median of 6.0. DNA index of the fresh tumour tissue
ranged with the ICP-22 flow cytometer between 1.2 and 2.9
(mean 1.98, median 1.9) and with the FACScan flow
cytometer between 2.6 and 3.8 (mean 3.37, median 3.5). The
quality ofthe DNA histograms ofthe carcinomas was similar
to that of the adenomas.
Figure 1 shows the frequency distribution of the measured
DNA indices of adrenocortical carcinomas (Figure la) and
adenomas (Figure lb). Six carcinomas were diploid (four
'wide CV' diploid; CV: 7.2, 7.5, 7.9, and 8.5). The other
carcinomas were all aneuploid: 15 hypo/hyperdiploid (the
two hypodiploid carcinomas were fresh), 28 hypo/
hypertetraploid and five tetraploid. Twenty-one adenomas
were diploid (ten of these 'wide CV' diploid). The remaining
nine adenomas were aneuploid: five hypo/hyperdiploid, two
hypo/hypertetraploid and three tetraploid. The difference in
DNA classes between carcinoma and adenoma was
significant (P<0.001). Clinical parameters (age, sex, hor-
monal presentation, tumour weight) and therapeutic
interventions (result of surgery, mitotane therapy) were not
related to DNA index.
Survival analysis
Survival of all patients with adrenocortical carcinoma is
shown in Figure 2; the differences between the four ploidy
Table I Characteristics ofpatients with adrenocortical tumours who
could be evaluated by flow cytometry
Carcinoma Adenoma
n =54 n =31
Age (years)
Mean (s.d.) 41.4 (17.0) 37.6 (15.1)
Range 1-78 11-64
Sex
Women 34 30
Men 20 1
Tumour localisation
Left 28 16
Right 26 15
Clinical manifestation
Hormonal 33 31
Non-hormonal 21 0
Metastases
No 33 31
Yes 21 0
Surgical resection
No 3 0
Subtotal 21 0
Total 30 31
Mitotane therapy'
No 21 31
Low 18 0
High 15 0
Tumour weight (g) n =42 n =26
Mean (s.d.) 750 (680) 24 (26)
Range 18-3000 5-120
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Figure 3 Actuarial survival rates from time of diagnosis in
patients with DNA diploid adrenocortical carcinomas compared
to patients with DNA aneuploid adrenocortical carcinomas.
(P<0.05).
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Figure 1 Frequency distribution of DNA index of adrenocor-
tical carcinoma a, and adenoma b. Each patient is represented by
*, with the exception of two carcinoma patients with DNA
indices of 3.27 and 3.82 respectively. Carcinoma
Adenoma :
NS1
Hypo/hyperdiploid
(n= 15) 0 4 6 81 I 2
o 2 4 6 8 10 12 14
ploid (n = 5)
Hypo/hypertraploid
(n= 28)
12 24 36 48
Month
60 72 84 96
16 18 20 22 24 26 28 30
Histological index
Figure 4 Histological index in 41 adrenocortical carcinomas and
20 adrenocortical adenomas. Four of the five adenomas with a
histological index between eight and 14 were DNA diploid,
whereas all carcinomas with a histological index between eight
and 14 were DNA aneuploid.
Figure 2 Actuarial survival rates from time of diagnosis in 54
patients with adrenocortical carcinoma according to ploidy class.
The differences between the four ploidy classes are not
significant.
classes are not significant. Patients with diploid carcinomas
had a significant shorter survival however, when compared to
patients with aneuploid tumours (P<0.05) (Figure 3). In the
30 patients who had a total tumour resection disease-free
survival was favourable in the patients with hypo/hyper-
diploid carcinomas compared to the other patients (P<0.05).
None of the clinical parameters (age, sex, hormonal presenta-
tion, tumour weight) was related to (disease free) survival.
Histological index
The histological index could be assessed in 61 (41 car-
cinomas, 20 adenomas) of the 85 patients, who were
evaluable for nuclear DNA content (Figure 4).
Five adenomas were found to have a histological index
above 8. Four of these adenomas were DNA diploid. All
carcinomas had a histological index above 8. The five car-
cinomas with a histological index between 8 and 14 (the
overlap zone between adenoma and carcinoma) were all
hypo/hyperdiploid. Five adenomas showed invasion of the
tumour capsule; four of these adenomas were DNA dip-
loid.
The histological index was not related to the DNA index.
However, five of the seven morphological parameters, were
individually related to (high) DNA index: a, the presence of
moderate or extensive regressive changes (P<0.01), b, the
loss of normal structure (P<0.05), c, moderate or strong
nuclear atypia (P = 0.05), d, the presence of moderate or
marked hyperchromasia (P<0.01), and e, invasion in vas-
cular wall and/or capsule (P = 0.01). The presence of more
than two mitotic figures per 10 highpower (400 x) fields, and
the structure of nucleoli were unrelated to the DNA index.
Survival of the adrenocortical carcinoma patients with a
tumour with a histological index above 20 was not different
compared to the patients with a histological index below 20.
Finally no difference was found in the histological index
between the group of patients with a very short survival, of
less than 6 months, and the patients who survived more than
3 years.
Discussion
The nuclear DNA content of adrenocortical carcinomas was
aneuploid in 89% of the patients. This observation is in
contrast to findings in the majority of human solid tumours
in which a higher percentage of DNA diploidy is observed.
For example DNA diploidy is found in breast cancer and
colorectal cancer in 20-30% of cases (Cornelisse & Tanke,
1991). Papillary carcinoma of the thyroid is found to be
DNA diploid in about 75% of the cases (Joensuu et al.,
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1988a; Schelfhout et al., 1990). Aneuploidy was found in our
series in 32% of the adrenocortical adenomas. Other inves-
tigators found a higher fraction, about 50%, of adrenocor-
tical adenomas to be DNA aneuploid (Joensuu & Klemi,
1988b; Padberg et al., 1991). Our findings of flow cytometric
DNA content analysis in adrenocortical tumours are, how-
ever, in line with the overall findings reported in literature as
summarised by Padberg et al. (1991).
In our study the difference between adrenocortical
adenoma and carcinoma in ploidy class and DI distribution
is evident. However, there is a clear overlap between the
adenoma and the carcinoma groups. Moreover, there are
adenomas with a DI of over 2.0. These aneuploid adenomas
have apparently followed a similar ploidy evolution as car-
cinomas without becoming clinically malignant. This suggests
that the accumulated chromosomal aberrations lack a final
oncogenic mutation and that tumours are 'frozen' in a
clinically premalignant state. These observations fit into the
hypothesis that adrenocortical carcinomas may arise from
existing, benign, adenomas.
The possible adenoma-carcinoma sequence is reflected by
the problems in the differentiation between adenoma and
carcinoma of the adrenal cortex (Hough et al., 1979; Weiss,
1984; van Slooten et al., 1985). Malignancy of an adrenal
tumour cannot be demonstrated by a single morphological
variable. However, with the histological index, determined by
seven histological parameters according to van Slooten et al.
(1985), a good differentiation between adenoma and car-
cinoma of the adrenal cortex is possible. An adrenocortical
tumour with a histological index below eight (maximum 28.4)
is considered to be benign.
On the basis of the histological index alone, especially
when the mitotic activity is low, the assessment of malig-
nancy may still be uncertain. In our study five adenomas
showed a histological index above eight. The histological
index of five carcinomas was also in the range between eight
and 14. In the patients with tumours with a histological index
between eight and 14, ploidy analysis showed that four of
five adenomas were DNA diploid, whereas all five car-
cinomas were aneuploid (hypo/hyperdiploid). These findings
indicate that flow cytometric analysis of adrenal tumours
with uncertain diagnosis is a valuable aid in the
differentiation between a benign and malignant adrenal
lesion.
We could not find a correlation between DNA ploidy and
the histological index. As would be expected, however, indivi-
dual histological characteristics directly resulting from
chromosomal abnormalities, such as nuclear hyperchromasia,
were related to nuclear DNA content. Remarkable in this
respect is that the mitotic activity, the best predictor of
malignancy, and the structure of nucleoli were not associated
with DI. We could not confirm the correlation between a
high histological index and short patient survival, as found in
a previous study (van Slooten et al., 1985). An explanation
for this difference may be the number of patients studied, or
the interpretation of the histological parameters by different
investigators.
When the survival of patients with adrenocortical car-
cinoma was related to the nuclear DNA content, a
significantly worse prognosis was observed in patients with a
DNA diploid tumour compared to patients with an aneu-
ploid tumour. In our study patients with a DNA hypo/
hyperdiploid tumour had significantly longer disease-free sur-
vival. This relationship between ploidy and survival is
different from that usually found in other solid tumours
(Cornelisse & Tanke, 1991), with often a worse prognosis
seen in patients with DNA aneuploid tumours. Our findings
are supported by the results reported by Hosaka et al. (1987),
who conducted the only study with a relatively large number
of patients, comparable to the number of patients in our
study. In that study, a short survival was found for patients
with a DNA diploid tumour who had a palliative tumour
resection, although this was not significant because of small
numbers.
The DNA index distribution of the adrenocortical car-
cinomas was not bimodal, with a clustering of DI round the
diploid and the hypotetraploid mode, as normally found in
solid tumours (Cornelisse & Tanke, 1991). A bimodal DNA
index frequency distribution, reflects two different
mechanisms of ploidy evolution. Mitotic non-disjunction or
chromosome segregation may lead to the development of
low-aneuploid tumours (DI<1.40). Tetraploidisation in com-
bination with gain or loss of individual chromosomes results
in high-aneuploid tumours, which were associated with a
worse prognosis.
With the worst prognosis in carcinomas with diploid DNA
content, it seems as if DNA ploidy evolution is behind the
process of cancer and metastases formation in these cases.
We cannot exclude that the 'wide CV' diploid tumours are
low grade aneuploid tumours with a small DNA index
beyond resolution, since the lowest hyperdiploid DNA index
measured in our series is 1.09. The distribution of DNA
index in the adrenocortical tumours studied, however, is in
line with the overall findings reported in literature as sum-
marised by Padberg et al. (1991). Moreover patients with
diploid tumours studied by Hosaka et al. (1987) showed the
same trend in survival.
An association of DNA diploidy with shorter survival has
been previously reported in neuroblastoma (Look et al.,
1984; Gansler et al., 1986; Oppedal et al., 1988; Abramowsky
et al., 1989). A cytogenetic study of neuroblastomas showed
that the karyotype of the majority of aneuploid tumours
consisted of three nearly complete haploid sets of
chromosomes, in contrast to that of diploid tumours, which
were characterised by extensive structural chromosomal aber-
rations (Kaneko et al., 1987). To our knowledge no
cytogenetic studies similar to that in neuroblastoma have
been performed for adrenocortical carcinoma.
From our findings so far, we conclude that a possible
adenoma-carcinoma sequence exists for the adrenal cortex.
As in neuroblastoma there seems to be a subgroup of car-
cinomas, that have progressed towards a clinically highly
aggressive phenotype, without developing gross DNA aneu-
ploidy. As such, the relationship between DNA-ploidy and
survival appears to deviate from that found for other solid
tumours. These data should be confirmed on a larger series
of patients in order to establish their clinical usefulness. The
histological index, and the mitotic index are not correlated to
DNA-ploidy.
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